title: Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
abstract: BACKGROUND
  Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage for a period of up to 5 years. The aim of this study was to evaluate the radiologic progression beyond that time in patients with early RA initially treated with a combination of three disease-modifying antirheumatic drugs (DMARDs) or a single DMARD.
  
  
  METHODS
  A cohort of 199 patients with early active RA were initially randomized to receive treatment with a combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone (FIN-RACo), or treatment with a single DMARD (initially, sulfasalazine) with or without prednisolone (SINGLE). After 2 years, the drug-treatment strategy became unrestricted, but still targeted remission. The radiographs of hands and feet were analyzed by using the Larsen score at baseline, 2, 5, and 11 years, and the radiographs of large joints, at 11 years.
  
  
  RESULTS
  Sixty-five patients in the FIN-RACo and 65 in the SINGLE group had radiographs of hands and feet available at baseline and at 11 years. The mean change from baseline to 11 years in Larsen score was 17 (95% CI, 12 to 26) in the FIN-RACo group and 27 (95% CI, 22 to 33) in the SINGLE group (P=0.037). In total, 87% (95% CI, 74 to 94) and 72% (95% CI, 58 to 84) of the patients in the FIN-RACo and the SINGLE treatment arms, respectively, had no erosive changes in large joints at 11 years.
  
  
  CONCLUSIONS
  Targeting to remission with tight clinical controls results in low radiologic progression in most RA patients. Patients treated initially with a combination of DMARDs have less long-term radiologic damage than do those treated initially with DMARD monotherapy.
  
  
  BACKGROUND
  Current Controlled Trials ISRCTN18445519.
authors.affiliation: Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. vappu.rantalaiho@uta.fi
authors.forename: Vappu
authors.initials: V
authors.lastname: Rantalaiho
authors.forename: Markku
authors.initials: M
authors.lastname: Korpela
authors.forename: Leena
authors.initials: L
authors.lastname: Laasonen
authors.forename: Hannu
authors.initials: H
authors.lastname: Kautiainen
authors.forename: Salme
authors.initials: S
authors.lastname: Järvenpää
authors.forename: Pekka
authors.initials: P
authors.lastname: Hannonen
authors.forename: Marjatta
authors.initials: M
authors.lastname: Leirisalo-Repo
authors.forename: Harri
authors.initials: H
authors.lastname: Blåfield
authors.forename: Kari
authors.initials: K
authors.lastname: Puolakka
authors.forename: Anna
authors.initials: A
authors.lastname: Karjalainen
authors.forename: Timo
authors.initials: T
authors.lastname: Möttönen
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000208:ethnology; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005387:Finland; D005500:Follow-Up Studies; D033023:Foot Joints / Q000000981:diagnostic imaging; D050823:Hand Joints / Q000000981:diagnostic imaging; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008137:Longitudinal Studies; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011859:Radiography; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D012460:Sulfasalazine; D006886:Hydroxychloroquine; D011239:Prednisolone; D008727:Methotrexate